OCM™
Chronic Wounds (e.g., Diabetic Foot Ulcers, Venous Leg Ulcers)
ApprovedActive
Key Facts
Indication
Chronic Wounds (e.g., Diabetic Foot Ulcers, Venous Leg Ulcers)
Phase
Approved
Status
Active
Company
About Omeza
Omeza is a private, pre-revenue biotech company targeting the large and underserved chronic wound care market with its proprietary Omega-3-based platform. Its lead candidate, OCM™, is a multimodal wound matrix designed to reduce biofilm, inflammation, and support tissue remodeling, aiming to prevent amputations and improve healing outcomes. The company is led by a lean executive team but is supported by a strategically experienced board with deep expertise in life sciences, commercialization, and government reimbursement. Omeza's success hinges on clinical validation, regulatory clearance, and achieving reimbursement for its novel therapeutic approach.
View full company profileTherapeutic Areas
Other Chronic Wounds (e.g., Diabetic Foot Ulcers, Venous Leg Ulcers) Drugs
| Drug | Company | Phase |
|---|---|---|
| Microlyte® SAM™ Commercial Launch | BioLab Holdings | Commercial |